**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Amira Zaroui
1/French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
2/ Cardiology department, Henri Mondor teaching hospital, Creteil, France
3/Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health”
Mounira Kharoubi : 1French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
2 /Cardiology department, Henri Mondor teaching hospital, Creteil, France
Melanie Bezard :  1French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
Romain Gounot:French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
3 /Lymphoid Malignancies Unit, Henri Mondor teaching Hospital, Creteil, France
4/ Paris XII University, UPEC, and IMRB-INSERM U955, Creteil, France.
François Lemonnier : French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
3 /Lymphoid Malignancies Unit, Henri Mondor teaching Hospital, Creteil, France
4/ Paris XII University, UPEC, and IMRB-INSERM U955, Creteil, France.
Thibaud Damy: 1French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
2 Cardiology department, Henri Mondor teaching hospital, Creteil, France
3Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health”

**Main Body of the Abstract**
Background.Prognostic staging of severe cardiac AL amyloidosis  are difficult due to low cut-off value of parameters used. Thus it is difficult to predict mortality in these severe patients. The objective of this study is to identify additional predictive factors of mortality in this population. Methods.This prospective de novo patients  cardiac AL amyloidosis at the Henri Mondor National Reference Centre. ResultsIn 233 de  patients , confirmed AL cardiac amyloidosis were included. Independent variables for mortality  include NT-ProBNP (3867 ng/L), hsTnT (107 ng/L), cardiac output and conjugated bilirubin (4 mmol/l) .Prognostic model identified NT proBNP, Troponin and Conjugated bilirubin as independent prognosticator. Mortality cut-off  were 107 ng/L for hsTnT, 3867 ng/L for NT-ProBNP and 4 mmol/L for CB. Mondor Amyloidosis Staging  (MAS) was calculated using a decisional tree: Stage 1: hsTnT≤107 pg/mL and NT-ProBNP value <3867ng/L (33%); Stage 2: hsTnT≤107 pg/mL and NT-ProBNP is >3867ng/L ( 30%). If troponin is above 107 pg/mL then CB is considered. Stage 3 was defined as CB ≤ 4mmol/l, ( 17.5%). Stage 4 was defined as CB >4mmol/l, (18.5%).The median survival with MAS: 22 months for stage 1 , 15.2  months for stage 2 ,6. months for stage 3  and 2 months for stage 4 . Patients classified as European stage IIIa, 12.5% were MAS 2 and 45 were MAS 3 . Among European stage IIIb, 16 were MAS stages 2, 43% were MAS3 .ConclusionThe Mondor prognostic staging system improve prognostic staging for patients with cardiac amyloidosis and severe cardiac



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Amira Zaroui
1/French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
2/ Cardiology department, Henri Mondor teaching hospital, Creteil, France
3/Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health”
Mounira Kharoubi : 1French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
2 /Cardiology department, Henri Mondor teaching hospital, Creteil, France
Melanie Bezard :  1French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
Romain Gounot:French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
3 /Lymphoid Malignancies Unit, Henri Mondor teaching Hospital, Creteil, France
4/ Paris XII University, UPEC, and IMRB-INSERM U955, Creteil, France.
François Lemonnier : French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
3 /Lymphoid Malignancies Unit, Henri Mondor teaching Hospital, Creteil, France
4/ Paris XII University, UPEC, and IMRB-INSERM U955, Creteil, France.
Thibaud Damy: 1French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, and DHU  Henri Mondor teaching hospital, APHP, Creteil, France
2 Cardiology department, Henri Mondor teaching hospital, Creteil, France
3Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health”

**Main Body of the Abstract**
**Background.**Prognostic staging of severe cardiac AL amyloidosis  are difficult due to low cut-off value of parameters used. Thus it is difficult to predict mortality in these severe patients. The objective of this study is to identify additional predictive factors of mortality in this population. **Methods.**This prospective de novo patients  cardiac AL amyloidosis at the Henri Mondor National Reference Centre. **Results**In 233 de  patients , confirmed AL cardiac amyloidosis were included. Independent variables for mortality  include NT-ProBNP (3867 ng/L), hsTnT (107 ng/L), cardiac output and conjugated bilirubin (4 mmol/l) .Prognostic model identified NT proBNP, Troponin and Conjugated bilirubin as independent prognosticator. Mortality cut-off  were 107 ng/L for hsTnT, 3867 ng/L for NT-ProBNP and 4 mmol/L for CB. Mondor Amyloidosis Staging  (MAS) was calculated using a decisional tree: Stage 1_:_ hsTnT≤107 pg/mL and NT-ProBNP value <3867ng/L (33%); Stage 2: hsTnT≤107 pg/mL and NT-ProBNP is >3867ng/L ( 30%). If troponin is above 107 pg/mL then CB is considered. Stage 3 was defined as CB ≤ 4mmol/l, ( 17.5%). Stage 4 was defined as CB >4mmol/l, (18.5%).The median survival with MAS: 22 months for stage 1 , 15.2  months for stage 2 ,6. months for stage 3  and 2 months for stage 4 . Patients classified as European stage IIIa, 12.5% were MAS 2 and 45 were MAS 3 . Among European stage IIIb, 16 were MAS stages 2, 43% were MAS3 .**Conclusion**The Mondor prognostic staging system improve prognostic staging for patients with cardiac amyloidosis and severe cardiac



Predictors factors of mortality in advanced cardiac AL Amyloidosis:A prospective Cohort study -  for improving cardiac stratification PA57 (#124)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.